SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for the Choline Fenofibrate Sustained-Release Capsules (135mg), which belongs to the category 4 of chemical drugs and is considered equivalent to passing a consistency evaluation. Choline Fenofibrate Sustained-Release Capsules are mainly used in adults to control diet and reduce the levels of high triglycerides in patients with severe hypertriglyceridemia. It is also used for the treatment of primary hypercholesterolemia or mixed dyslipidemia patients. Compared to traditional fenofibrate, Choline Fenofibrate has a direct effect, lower burden on the liver and kidneys, no restrictions on medication with food, and can be safely combined with statin drugs, making it a high-end substitute product for lowering triglycerides in clinical demand.